<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities center on AI-powered multi-omics diagnostics, personalized preventive care, at-home testing, wearables, biosensors, and early detection of disease and aging risks<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 Biological Age and Longevity Diagnostics Market
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/ab91746b-ddcb-41c8-9918-c0588c692c97" title="Biological Age and Longevity Diagnostics Market" alt="Biological Age and Longevity Diagnostics Market" />
 <figcaption>Biological Age and Longevity Diagnostics Market</figcaption>
 </figure>
</div>Dublin, Sept. 03, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6264102/biological-age-longevity-diagnostics-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3sfzrl&amp;utm_campaign=2344673+-+Biological+Age+and+Longevity+Diagnostics+Market+to+Reach+%245.58+Billion+by+2030+as+Personalized+Medicine+Adoption+Accelerates+-+Profiles+of+Elysium+Health%2c+InsideTracker%2c+TruDiagnostic+and+More&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Biological Age and Longevity Diagnostics Market Global Report 2026">"Biological Age and Longevity Diagnostics Market Global Report 2026"</a> has been added to ResearchAndMarkets.com's offering. The global biological age and longevity diagnostics market is experiencing rapid expansion, driven by advances in precision healthcare, biomarker testing and aging research. The market is projected to grow from $2.9 billion in 2025 to $3.31 billion in 2026, representing a compound annual growth rate (CAGR) of 14.3%. <img alt="" height="400" src="//www.researchandmarkets.com/content-images/2529/2529544/1/biological-age-and-longevity-diagnostics-market.png" width="600" /> Historical market growth has been supported by the increasing use of genomic sequencing in clinical research, greater emphasis on preventive healthcare and early disease detection, and wider adoption of biomarker-based diagnostic testing. Additional growth factors include expanding biotechnology research focused on aging and the continued integration of healthcare digitization and electronic health records. The biological age and longevity diagnostics market is forecast to reach $5.58 billion by 2030, expanding at a CAGR of 13.9%. Growth during the forecast period is expected to be fueled by AI-powered precision medicine platforms, rising demand for personalized healthspan solutions, greater integration of multi-omics analytics and the expansion of direct-to-consumer longevity testing services. Advances in real-time biosensors, wearable diagnostics and digital health monitoring are also expected to improve access to biological age assessments. Key biological age and longevity diagnostics market trends include the growing integration of genomic, epigenomic, proteomic and metabolomic data to improve biological age prediction and healthspan assessment. AI-driven longevity models are increasingly being used to connect biomarkers with disease risks and aging trajectories. Demand is also rising for early disease prediction based on molecular and epigenetic aging signatures, personalized anti-aging programs, and microbiome and metabolic profiling. The increasing adoption of personalized medicine is a major driver of market growth. Advances in genomics and molecular diagnostics allow healthcare providers to evaluate individual genetic profiles and biomarkers, supporting more precise prevention and treatment strategies. Biological age and longevity diagnostics contribute to this approach by identifying molecular, genetic and physiological indicators of aging. These insights can help clinicians develop more targeted lifestyle, prevention and treatment programs than those based on chronological age alone. Personalized treatment approvals further demonstrate the growing role of precision healthcare. According to the Personalized Medicine Coalition, the US Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, compared with six in 2022. Approvals during 2023 also included seven cancer drugs and three therapies addressing other diseases and conditions. This momentum is expected to increase demand for biological age testing and longevity diagnostics across clinical and consumer healthcare settings. Innovation is also reshaping the competitive landscape. In April 2026, Thrive Global launched the Elite Longevity Assessment, a multi-omics longevity platform that combines advanced biomarker panels, metabolic profiling and lifestyle data. AI-powered analytics generate individualized aging scores and healthspan forecasts, supporting the identification of accelerated aging and underlying health risks. The platform also provides personalized recommendations involving nutrition, supplementation and lifestyle optimization, shifting the focus of health assessments toward preventive care and long-term health management. Market consolidation is supporting the development of integrated longevity platforms. In April 2026, Infinite Epigenetics acquired Tally Health for an undisclosed amount. The acquisition combines Infinite Epigenetics' epigenetic diagnostic capabilities with Tally Health's at-home biological age testing, personalized longevity recommendations and healthy aging services. The transaction is intended to create a vertically integrated healthspan platform serving the expanding biological age and longevity diagnostics market. North America was the largest region in the biological age and longevity diagnostics market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain. Markets Covered: 1) By Test Type: Epigenetic Age Testing; Telomere Length Testing; Multi Omics Diagnostics; Proteomic Aging Tests; Microbiome Based Longevity Diagnostics; Cellular Senescence Biomarker Tests; Organ Age Assessment Tests 2) By Sample Type: Blood Samples; Saliva Samples; Urine Samples; Tissue Samples; Buccal Swab Samples; Hair Samples 3) By Application Type: Preventive Healthcare; Personalized Medicine; Chronic Disease Risk Assessment; Wellness And Fitness Monitoring; Anti Aging Research 4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Longevity Clinics; Academic Institutions; Direct To Consumer Users; Pharmaceutical And Biotechnology Companies Subsegments: 1) By Epigenetic Age Testing: Deoxyribonucleic Acid Methylation Testing; Histone Modification Analysis; Chromatin Accessibility Profiling; Epigenetic Clock Assessment; Age Prediction Biomarker Testing 2) By Telomere Length Testing: Quantitative Polymerase Chain Reaction Testing; Flow Cytometry And Fluorescence In Situ Hybridization; Southern Blot Analysis; Single Telomere Length Analysis; Telomerase Activity Testing 3) By Multi Omics Diagnostics: Genomics Analysis; Transcriptomics Analysis; Proteomics Analysis; Metabolomics Analysis; Lipidomics Analysis 4) By Proteomic Aging Tests: Plasma Protein Biomarker Testing; Inflammatory Protein Analysis; Cytokine Profiling; Enzyme Activity Analysis; Growth Factor Biomarker Testing 5) By Microbiome Based Longevity Diagnostics: Gut Microbiome Sequencing; Microbial Diversity Analysis; Functional Microbiome Profiling; Stool Biomarker Testing; Microbial Metabolite Analysis 6) By Cellular Senescence Biomarker Tests: Senescence Associated Beta Galactosidase Testing; Cellular Stress Marker Analysis; Cell Cycle Arrest Biomarker Testing; Senescence Secretory Phenotype Profiling; Deoxyribonucleic Acid Damage Response Testing 7) By Organ Age Assessment Tests: Cardiovascular Age Assessment; Brain Age Assessment; Liver Age Assessment; Kidney Age Assessment; Lung Age Assessment Time Series: Five years historic and ten years forecast. Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita. Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments. Key Attributes <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">250</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026-2030</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$3.31 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2030</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$5.58 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">13.9%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Companies Featured <ul><li>Altos Labs</li><li>Infinite Epigenetics</li><li>TruDiagnostic</li><li>Viome Life Sciences Inc.</li><li>Function Health</li><li>Elysium Health Inc.</li><li>InsideTracker Inc.</li><li>Segterra Inc.</li><li>Human Longevity Inc.</li><li>FOXO Technologies Inc.</li><li>GlycanAge Ltd.</li><li>Gero PTE. Ltd.</li><li>Decode Age Technologies Pvt. Ltd.</li><li>MyDNAge Inc.</li><li>Generation Lab</li><li>SiPhox Inc</li><li>Neko Health</li><li>Circulate Health</li><li>EpiMedTech Global</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6264102/biological-age-longevity-diagnostics-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3sfzrl&amp;utm_campaign=2344673+-+Biological+Age+and+Longevity+Diagnostics+Market+to+Reach+%245.58+Billion+by+2030+as+Personalized+Medicine+Adoption+Accelerates+-+Profiles+of+Elysium+Health%2c+InsideTracker%2c+TruDiagnostic+and+More&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/98olmj</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/ab91746b-ddcb-41c8-9918-c0588c692c97" title="Biological Age and Longevity Diagnostics Market" rel="nofollow">Biological Age and Longevity Diagnostics Market</a>
 </li>
 </ul>
<pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZWIwYTJkMzUtZjI3Mi00ZmQ4LWI4ODQtODc2MmE2MTFjMTBhLTEwMjY3MzctMjAyNi0wOS0wMy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Biological Age and Longevity Diagnostics Market to Reach $5.58 Billion by 2030 as Personalized Medicine Adoption Accelerates - Profiles of Elysium Health, InsideTracker, TruDiagnostic and More

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn